Government Briefs

Ever since President Reagan took office, the NIH budget has been a political football—artificially low requests handed off by the president have crossed the goal line as sizable increases in the final appropriations measure passed by Congress. But that tradition could end this year. The Reagan request for a small 6.8% increase over this year’s budget is being taken seriously on Capitol Hill, and it appears likely that the final figures for NIH will be only slightly higher. In June,

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Ever since President Reagan took office, the NIH budget has been a political football—artificially low requests handed off by the president have crossed the goal line as sizable increases in the final appropriations measure passed by Congress. But that tradition could end this year. The Reagan request for a small 6.8% increase over this year’s budget is being taken seriously on Capitol Hill, and it appears likely that the final figures for NIH will be only slightly higher. In June, the House approved a bill to add $60 million to the administration’s request for $7.122 billion, earmarking it for more than a dozen non-AIDS programs across the institutes. The Senate appropriations committee later added $77 million, including an additional $31 million (on top of the president’s $588 million request) for AIDS programs, as part of its own laundry list of special programs. The House bill also calls for 300 new ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies